TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy

被引：52

作者：

Bonfiglio, Vincenza ^{[1
]}

Platania, Chiara Bianca Maria ^{[2
]}

Lazzara, Francesca ^{[2
]}

Conti, Federica ^{[2
]}

Pizzo, Corrado ^{[3
]}

Reibaldi, Michele ^{[4
]}

Russo, Andrea ^{[3
]}

Fallico, Matteo ^{[3
]}

Ortisi, Elina ^{[3
]}

Pignatelli, Francesco ^{[5
]}

Longo, Antonio ^{[3
]}

Avitabile, Teresio ^{[3
]}

Drago, Filippo ^{[2
,6
]}

Bucolo, Claudio ^{[2
,6
]}

机构：

[1] Univ Palermo, Ophthalmol Sect, Dept Expt Biomed & Clin Neurosci, I-90133 Palermo, Italy

[2] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy

[3] Univ Catania, Dept Ophthalmol, I-95123 Catania, Italy

[4] Univ Torino, Dept Surg Sci, Eye Clin, I-10124 Turin, Italy

[5] SS Annunziata Hosp, Dept Ophthalmol, I-74121 Taranto, Italy

[6] Univ Catania, Ctr Res Ocular Pharmacol CERFO, I-95123 Catania, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 24期

关键词：

diabetic retinopathy; serum biomarkers; anti-VEGFA; TGFβ ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL INJECTION; AFLIBERCEPT; TGF-BETA-1; RANIBIZUMAB; BEVACIZUMAB; INVOLVEMENT; FEATURES;

D O I：

10.3390/ijms21249558

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Transforming growth factor beta 1 (TGF beta 1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGF beta 1 as a diagnostic and prognostic biomarker of DR stages. Thirty-eight subjects were enrolled and, after diagnosis and evaluation of inclusion and exclusion criteria, were assigned to six groups: (1) healthy age-matched control, (2) diabetic without DR, (3) non-proliferative diabetic retinopathy (NPDR) naive to treatment, (4) NPDR treated with intravitreal (IVT) aflibercept, (5) proliferative diabetic retinopathy (PDR) naive to treatment and (6) PDR treated with IVT aflibercept. Serum levels of vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF) and TGF beta 1 were measured by means of enzyme-linked immunosorbent assay (ELISA). Foveal macular thickness (FMT) in enrolled subjects was evaluated by means of structural-optical coherence tomography (S-OCT). VEGF-A serum levels decreased in NPDR and PDR patients treated with aflibercept, compared to naive DR patients. PlGF serum levels were modulated only in aflibercept-treated NPDR patients. Particularly, TGF beta 1 serum levels were predictive of disease progression from NPDR to PDR. A Multivariate ANOVA analysis (M-ANOVA) was also carried out to assess the effects of fixed factors on glycated hemoglobin (HbA1c) levels, TGF beta 1, and diabetes duration. In conclusion, our data have strengthened the hypothesis that TGF beta 1 would be a biomarker and pharmacological target of diabetic retinopathy.

引用

页码：1 / 16

页数：16

共 49 条

[1] Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients [J].